Comments
Glenmark Pharmaceuticals has filed arbitration claims against Napo Pharmaceuticals Inc with the American Arbitration Association, seeking a declaration of its exclusive rights to diarrhoea drug Crofelemer in 140 countries.
The statement seeks a declaration of exclusive rights to develop, commercialise and distribute Crofelemer in 140 countries, including exclusive right to distribute the drug through relief agencies in these countries, Glenmark said in a filing to the Bombay Stock Exchange today.
The claims seek to prevent Napo from distributing these products through relief agencies in these countries, it added.
“Glenmark has an exclusive licence from Napo to develop, commercialise and distribute Crofelemer in 140 countries for specific indications,” it said.
The company said it has the resources, capability and commitment to address relief agency distribution in emerging countries, as per the licensing agreement.
Meanwhile, the scrip was trading at Rs 317 in the afternoon session on the BSE today, down 1.49 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.